CHRO — ChromoGenics AB Income Statement
0.000.00%
Last trade - 00:00- SEK64.85m
- SEK85.06m
- SEK13.65m
Annual income statement for ChromoGenics AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 45.2 | 14.6 | 24.7 | 18.3 | 13.6 |
| Cost of Revenue | |||||
| Gross Profit | -3.22 | 0.141 | 8.75 | 3.3 | 7.08 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 120 | 71.4 | 84.3 | 74.2 | 62.4 |
| Operating Profit | -74.9 | -56.8 | -59.7 | -55.9 | -48.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -77.9 | -62.5 | -63.5 | -57 | -52.5 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -77.9 | -62.5 | -63.5 | -57 | -52.5 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -77.9 | -62.5 | -63.5 | -57 | -52.5 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -77.9 | -62.5 | -63.5 | -57 | -52.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -99,334 | -18,994 | -27,120 | -2,896 | -19.8 |
| Dividends per Share |